VIB spin-off MRM Health completes patient recruitment in Ulcerative Colitis study, secures financing and provides outlook for 2023
A business update on MRM Health's different ongoing therapeutic programs and an outlook for 2023
MRM Health — a VIB spin-off company founded in 2020, focused on developing next-generation live microbiome consortia therapeutics — today provided a business update on its different ongoing therapeutic programs and an outlook for 2023.
An important milestone for the company's Ulcerative Colitis therapeutic was reached as MRM Health completed patient enrolment for its phase 2a trial with next-generation live microbiome consortia therapeutic MH002. The company is expecting to have topline results in the third quarter of 2023. To booth, the company currently also has an ongoing patient enrolment for its open-label phase 2 trial in Acute Pouchitis, a rare disease linked to Ulcerative Colitis or other bowel diseases.
Additionally, MRM Health was able to attract SFPIM, the Belgian Sovereign Wealth Fund, as a new investor. Complementary, the company also obtained additional financing from existing investors and SFPIM to extend the company’s runway and further build the clinical and preclinical pipeline.
Adding to this, upon achieving preclinical development targets within its partnered program in Type 2 Diabetes, MRM Health also secured a next milestone payment from IFF. Complementary, the company was also awarded a grant in the amount of 2 million euros from the Flemish Agency for Innovation and Entrepreneurship, VLAIO, to further accelerate its preclinical program in Parkinson's Disease.
The cherry on the cake for what is turning out to be an excellent week for MRM Health, is that the company has obtained 3 more granted US patents and has filed for 2 novel international patent applications to further strengthen its IP portfolio.
Sam Possemiers, CEO of MRM Health: “In 2022, we delivered not only on key milestones regarding the progress of our clinical programs, but also on key preclinical targets and we obtained additional dilutive and non-dilutive financing to continue our ambitious growth plans. 2023 also started very promising as we reached a major milestone by completing early January patient recruitment in the Phase 2a study with MH002 in Ulcerative Colitis, while patient recruitment in our phase 2 study in Acute Pouchitis continues to progress. Leveraging on the power of our CORAL® platform and building further on the successes from 2022, our preclinical programs in Type 2 Diabetes (T2D), non-alcoholic fatty liver disease (NAFLD) and Parkinson’s Disease will further advance, with preclinical proof-of-concept expected in 2023 for the T2D program. Our effective progress provided confidence to SFPIM to join MRM Health and to partner with our existing investors to close a follow-on financing to continue on our path to success."
